I am a first-year PhD student in Systems Biology at Columbia University Irving Medical Center. Before my PhD, I completed my undergraduate training at the School of Life Sciences, Peking University with a major in Bioinformatics.

📰 News

2025.11 — 📄 Paper published in Cell Mol Immunol on T-cell metabolism and SARDH
2025.09 — 🎉 Started PhD in Systems Biology at Columbia University Irving Medical Center
2025.06 — 🎓 Graduated from Peking University with the Shen Tong Outstanding Undergraduate Award
2025.05 — 📄 Paper published in Cell on immune heterogeneity in anti-PD-1 treated NSCLC
2024.07 — 📄 Paper published in Cell Reports Medicine on neoadjuvant immunotherapy in NSCLC

🔬 Research

My research focuses on developing and applying computational frameworks to decode the multiscale regulatory logic of biological systems in health and disease. Specifically, I am interested in:

Tumor Immune Microenvironment — Utilizing single-cell and spatial omics to dissect the complexity of the tumor immune microenvironment and identify mechanisms of therapy resistance
Spatiotemporal Algorithms — Developing spatiotemporal algorithms to infer how spatial organization and intercellular signaling drive cellular phenotypes and tissue morphogenesis
Gene Regulatory Networks — Leveraging rapid protein perturbation systems to capture transient transcriptional dynamics, thereby uncovering the direct gene regulatory networks that govern cellular decision-making

By bridging these dimensions, I aim to transform static molecular snapshots into predictive, dynamical models of complex biological processes.

🎓 Education

2025.09 - Present, Columbia University Irving Medical Center, New York, USA, PhD Student in Systems Biology
2021.09 - 2025.06, Peking University, Beijing, Bachelor of Engineering in Bioinformatics

📝 Publications

Chao Zhang, Yuxuan Sun, Dingcheng Yi, Benyuan Jiang, Lixu Yan, …, Zemin Zhang, Wenzhao Zhong. Neoadjuvant sintilimab plus chemotherapy in early-stage EGFR-mutant NSCLC: phase 2 trial interim results (NEOTIDE/CTONG2104). Cell Reports Medicine, 2024

Abstract

The clinical efficacy of neoadjuvant immunotherapy plus chemotherapy remains elusive in localized epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). Here, we report interim results of a Simon's two-stage design, phase 2 trial using neoadjuvant sintilimab with carboplatin and nab-paclitaxel in resectable EGFR-mutant NSCLC. All 18 patients undergo radical surgery, with one patient experiencing surgery delay. Fourteen patients exhibit confirmed radiological response, with 44% achieving major pathological response (MPR) and no pathological complete response (pCR). Similar genomic alterations are observed before and after treatment without influencing the efficacy of subsequent EGFR-tyrosine kinase inhibitors (TKIs) in vitro. Infiltration and T cell receptor (TCR) clonal expansion of CCR8+ regulatory T (Treg)hi/CXCL13+ exhausted T (Tex)lo cells define a subtype of EGFR-mutant NSCLC highly resistant to immunotherapy, with the phenotype potentially serving as a promising signature to predict immunotherapy efficacy. Informed circulating tumor DNA (ctDNA) detection in EGFR-mutant NSCLC could help identify patients nonresponsive to neoadjuvant immunochemotherapy. These findings provide supportive data for the utilization of neoadjuvant immunochemotherapy and insight into immune resistance in EGFR-mutant NSCLC.

Zedao Liu, Zhenlin Yang, Junqi Wu, Wenjie Zhang, Yuxuan Sun, Chao Zhang, Guangyu Bai, …, Dingcheng Yi, …, Zemin Zhang. A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer. Cell, 2025

Abstract

Anti-PD-(L)1 treatment is standard for non-small cell lung cancer (NSCLC), but patients show variable responses to the same regimen. The tumor immune microenvironment (TIME) is associated with immunotherapy response, yet the heterogeneous underlying therapeutic outcomes remain underexplored. We applied single-cell RNA and TCR sequencing (scRNA/TCR-seq) to analyze surgical tumor samples from 234 NSCLC patients post-neoadjuvant chemo-immunotherapy. Analyses revealed five distinct TIME subtypes with varying major pathological response (MPR) rates. MPR patients had elevated levels of FGFBP2+ NK/NK-like T cells, memory B cells, or effector T cells, while non-MPR patients showed higher CCR8+ Tregs. T cell clonal expansion analyses unveiled heterogeneity in non-MPR patients, marked by varying expansions of Tex-relevant cells and CCR8+ Tregs. Precursor exhausted T cells (Texp cells) correlated with recurrence-free survival, identifying a patient subgroup with reduced recurrence risk despite lack of MPR. Our study dissects TIME heterogeneity in response to chemoimmunotherapy, offering insights for NSCLC management.

Wen Si, Sijin Cheng, Haiyin He, Yu Zhang, Yuhui Miao, Dingcheng Yi, Mengjiao Ni, Anqiang Wang, Hongtao Fan, Yufei Bo, Chang Liu, Zhaode Bu, Linnan Zhu, Zemin Zhang. SARDH in the 1-C metabolism sculpts the T-cell fate and serves as a potential cancer therapeutic target. Cell Mol Immunol, 2025

Abstract

T-cell metabolism plays a pivotal role in defining T-cell functional states. Through analysis of a comprehensive pancancer single-cell transcriptional atlas, we identified SARDH, an enzyme involved in one-carbon (1-C) metabolism, as a potential T-cell metabolic checkpoint. SARDH significantly impacts T-cell fate and function, leading to impaired tumor control efficacy. Knocking down SARDH resulted in sarcosine accumulation and reduced consumption of S-adenosylmethionine (SAM), a critical methyl donor for epigenetic modulation, likely due to the shift in glycine-to-sarcosine homeostasis. Deletion of SARDH increased H3K79me2 modification at NF-κB-activating genes, thereby augmenting NF-κB signaling and T-cell function. Additionally, we observed transcriptional dysregulation of 1-C metabolism within tumors across various cancer types, which was often accompanied by increased sarcosine levels. Sarcosine was found to induce SARDH upregulation, suggesting a feedback mechanism for metabolic homeostasis in T cells within tumors. These findings underscore the potential effects and mechanism of targeting 1-C metabolism, particularly SARDH, as an avenue for cancer therapy.

🏆 Honors & Awards

Award	Year
Shen Tong Outstanding Undergraduate Award, highest honor for undergraduates in the department	2025
National Scholarship	2024
Pacemaker to Merit Student	2024
May 4th Scholarship, highest individual scholarship at Peking University	2023
Award for Academic Excellence	2022, 2023
Qin Wanshun-Jin Yunhui Scholarship	2022

🤝 Open for Collaboration

I am actively seeking collaborations in the following areas:

Multi-modal single-cell analysis — Integration of scRNA-seq, scATAC-seq, and spatial transcriptomics
Tumor microenvironment modeling — Computational approaches to understand immune-tumor interactions
Biomarker discovery — Machine learning methods for identifying therapeutic response predictors

If you are working on related problems or have interesting datasets, I would love to connect!

📧 dy2527@cumc.columbia.edu · 💼 LinkedIn

🎮 Beyond Research

I love playing the Rubik’s Cube and diving into geeky pursuits like Arch Linux and Emacs. I’m also a big anime fan — my favorite is Liz and the Blue Bird.

📄 CV

Download my latest CV: Dingcheng Yi CV (PDF)